BlackRock, Inc. 13D and 13G filings for Verve Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2025-04-17 5:40 pm Sale |
2025-03-31 | 13G | Verve Therapeutics, Inc. VERV |
BLACKROCK INC BLK |
6,177,751 7.000% |
-1,098,596![]() (-15.10%) |
Filing |
2025-04-17 09:35 am Purchase |
2025-03-31 | 13G | Verve Therapeutics, Inc. VERV |
BLACKROCK INC BLK |
6,177,751 7.000% |
6,177,751![]() (New Position) |
Filing |
2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Verve Therapeutics, Inc. VERV |
BLACKROCK INC BLK |
7,276,347 8.600% |
0 (Unchanged) |
Filing |
2024-10-22 3:24 pm Purchase |
2024-09-30 | 13G | Verve Therapeutics, Inc. VERV |
BLACKROCK INC BLK |
7,276,347 8.600% |
2,840,866![]() (+64.05%) |
Filing |
2024-01-29 5:25 pm Purchase |
2023-12-31 | 13G | Verve Therapeutics, Inc. VERV |
BLACKROCK INC BLK |
4,435,481 5.600% |
4,435,481![]() (New Position) |
Filing |